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Summary
Background.— Immunoglobulinic (AL) amyloidosis is a complication of plasma cell dyscra-Restrictive
cardiomyopathy;
Serum free light
sia, characterized by widespread deposition of amyloid ﬁbrils derived from monoclonal light
chains. Cardiac amyloid is the main prognostic factor, with a median survival of six months.
Cardiac transplantation in AL amyloidosis is associated with high mortality, due to disease
recurrence in the allograft and systemic progression. Suppression of light chain (LC) production
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Conclusion.— Un traitement hématologique approprié, notamment la chimiothérapie de type
MD permet une survie prolongée chez les patients greffés cardiaques pour une cardiopathie
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bbreviations
BMT allogeneic bone marrow transplantation
L immunoglobulinic
NP brain natriuretic peptide
DM/ASCT high dose melphalan + autologous stem cell
transplantation
VEF left ventricular ejection fraction
D melphalan plus dexamethasone
T-proBNP N-terminal pro-brain natriuretic peptide
YHA New York Heart Association
FLC serum free light chain
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ackground
L amyloidosis is a systemic disorder, usually caused by
smouldering clonal plasma cell disorder producing mon-
clonal light chains (LC) that undergo conformational
odiﬁcations and aggregate into amyloid ﬁbrils [1]. Amyloid
bril deposits commonly affect the kidneys, heart, liver, andA. Mignot et al.
with chemotherapy by melphalan plus dexamethasone (MD) or high dose melphalan followed by
autologous stem cell transplantation (HDM/ASCT) improves survival. However, both the indica-
tions and results of chemotherapy in patients transplanted for cardiac AL amyloidosis remain
unclear.
Aims.— To assess the outcome of cardiac transplantation and haematological therapy in
patients with cardiac AL amyloidosis.
Methods.— Eight French patients, who underwent heart transplantation for cardiac AL amyloi-
dosis between 2001 and 2006 were studied retrospectively.
Results.— Before transplantation, six patients received MD (n = 5) or HDM/ASCT (n = 1). Haema-
tological remission was obtained in three patients treated with MD. In the three remaining
patients, postoperative HDM/ASCT (n = 2) or allogeneic bone marrow transplantation (n = 1)
resulted in haematological remission in one patient. In 2 patients not treated before trans-
plantation, post-operative treatment with MD resulted in complete hematological remission
in one. After a median follow-up of 26 months from cardiac transplantation, six patients were
alive and four had sustained haematological remission, as indicated by normal serum free LC
levels.
Conclusion.— Appropriate haematological therapy, including MD, may result in a survival beneﬁt
in AL amyloidosis patients with advanced heart failure requiring transplantation.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Avant propos.— L’atteinte cardiaque conditionne le pronostic de l’amylose AL, avec une
médiane de survie inférieure à six mois. La transplantation cardiaque (TxC) dans l’amylose
AL est associée à une mortalité élevée, liée à la récidive sur le greffon des dépôts de chaînes
légères (CL) d’immunoglobuline monoclonale et à la progression systémique de la maladie.
La suppression de la production de CL par la chimiothérapie conventionnelle par melphalan
et dexamethasone (MD) ou le traitement intensif par melphalan haute dose et autogreffe de
cellules souches hématopoïétiques, permet d’améliorer la survie. Cependant, les indications et
les résultats de la chimiothérapie chez les patients transplantés cardiaques pour une amylose
AL demeurent mal connus.
Objectifs.— Évaluer les résultats de la transplantation cardiaque (TxC) dans l’amylose AL en
France.
Méthodes.— Huit patients greffés cardiaques entre 2001 et 2006 pour une cardiopathie amy-
loïde AL ont été étudiés rétrospectivement.
Résultats.— Avant la TxC, cinq patients ont rec¸u une chimiothérapie par MD et un patient un
traitement intensif, avec une rémission hématologique dans trois cas. Chez les trois patients
non-répondeurs, le traitement intensif post-TxC avec autogreffe ou allogreffe de moëlle (un
patient) a entraîné la rémission hématologique dans un seul cas. Sur deux patients non traités
avant la greffe cardiaque, une rémission hématologique complète a été obtenue dans un
cas après une chimiothérapie par MD en postopératoire. Avec suivi de 26mois postgreffe, six
patients sont vivants et quatre en rémission hématologique prolongée.eripheral and autonomic nervous system [2]. Restrictive
ardiomyopathy is a severe and frequent complication of
L amyloidosis, with a 20% prevalence of symptomatic car-
iomyopathy at diagnosis. Clinical manifestations progress
ver time, ranging from asymptomatic electrocardiographic
B
T
3
m
i
i
A
a
t
c
t
v
a
e
n
m
s
r
p
a
w
t
a
T
[
R
F
a
a
F
i
A
d
c
c
c
s
oHeart transplantation and systemic amyloidosis
changes (low voltages in the limb leads) to rhythm abnormal-
ities, atheroembolism, myocardial ischaemia, conduction
blocks, heart failure, and sudden death. The overall progno-
sis of patients with AL amyloidosis is poor, ranging from 12
to 24 months. Cardiac amyloid is the main prognostic fac-
tor, with a median survival of approximately nine months in
symptomatic patients and less than six months at the stage
of congestive heart failure [3].
Cardiac transplantation has been performed in a small
number of patients with AL amyloidosis [4—13]. Its indi-
cation remains controversial because of organ shortage,
recurrence of amyloid deposition in the graft, and pro-
gression of the disease, with severe systemic symptoms
related to widespread organ involvement. Recent reports
have shown encouraging results, with long-term survival in
patients with AL amyloidosis and predominant cardiomyopa-
thy after sequential heart transplantation followed by high
dose melphalan therapy and autologous stem cell transplan-
tation (HDM/ASCT) [10] or even allogeneic bone marrow
transplantation (ABMT) [11]. In heart recipients, in whom
remission of the underlying plasma cell disorder is achieved
with HDM/ASCT, amyloid deposits do not recur in the allo-
graft and the systemic progression of the disease is stopped,
resulting in prolonged survival [10]. However, this proce-
dure is applicable only to selected cases, as many patients
with multiple organ deposits are not eligible for HDM/ASCT
because of high treatment-related mortality [14]. We report
here the French experience of heart transplantation for
amyloid heart disease from 2001 to 2006. At variance with
other previous reports, all patients had multiple organ
involvement at the time of transplantation.
Methods
All patients who underwent cardiac transplantation for AL
amyloid cardiomyopathy were identiﬁed by questioning the
databases of the 13 French heart transplant centres. The
diagnosis of AL amyloidosis was conﬁrmed histologically in
all cases by immunoﬂuorescence or immunohistochemistry
performed on cardiac or extracardiac biopsy samples, using
speciﬁc antilambda or antikappa conjugates. Demonstra-
tions of underlying plasma cell dyscrasia was searched for in
all patients using bone marrow smears and/or trephine, cou-
pled with serum and urine immunoelectrophoresis. Serum
free light chain (sFLC) levels were measured, whenever pos-
sible, with the Freelite® nephelometric assay (Binding Site,
t
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Table 1 Patient baseline characteristics.
Patient Sex Age (years) Ligh
1 Male 29 Lam
2 Male 60 Kap
3 Female 56 Lam
4 Male 62 Lam
5 Female 47 Lam
6 Female 43 Kap
7 Male 46 Lam
8 Male 45 Lam
% PC, percentage of mature plasma cells on bone marrow biopsy/smea525
irmingham, UK), which became available for use in 2003.
he normal ranges of kappa and lambda light chains are
.6—16mg/L and 8.10—33mg/L, respectively, and the nor-
al range for the kappa/lambda ratio is 0.36—1mg/L. Organ
nvolvement was deﬁned according to the Consensus Opin-
on from the 10th International Symposium on Amyloid and
myloidosis [15]. The diagnosis of amyloid heart disease was
ssessed as follows: presence of low voltage on 12-lead elec-
rocardiography, associated with features of hypertrophic
ardiomyopathy (mean septum thickness greater or equal
o 12mm in the absence of other potential causes of left
entricular hypertrophy) [15]. Systolic function was evalu-
ted using Simpson’s method of estimation of left ventricular
jection fraction (LVEF). When available, serum N termi-
al pro brain natriureticpeptide (NT-proBNP) levels were
onitored using an electrochemiluminescence immunoas-
ay (Roche, Basel, Switzerland). Complete haematological
esponse to treatment was deﬁned as the complete disap-
earance of the monoclonal immunoglobulin or light chain in
serum or urine specimen; partial haematological response
as deﬁned as greater than 50% reduction in these pro-
eins. Baseline clinical characteristics, survival outcomes
nd mortality for the entire cohort were also analysed.
wo cases from the present series were reported previously
12,13].
esults
rom 2001 to 2006, eight patients (ﬁve men, three women)
ged 48.5± 10.7 years (range 29—62) at the time of AL
myloidosis diagnosis, underwent cardiac transplantation in
rance. Main baseline clinical and haematological character-
stics are shown in Tables 1 and 2. Histological diagnosis of
L amyloidosis was established on skin (n = 4), endomyocar-
ial (n = 3) and kidney (n = 1) biopsies, with amyloid deposits
omposed of lambda light chains in six cases and kappa light
ases in two patients. A serum and/or urine monoclonal
omponent was found in all cases. Only two patients had
igniﬁcant plasma cell bone marrow inﬁltration, indicative
f smouldering myeloma.
All patients had severe systemic involvement at presen-
ation, with a mean number of 4.3 (range 3—7) affected
rgans or tissues at presentation. Extracardiac amyloid
ccumulation was detected in the skin/soft tissue (n = 7),
idney (n = 6), peripheral nervous system (n = 6), liver
n = 4), upper digestive tract (n = 3), and lung (n = 1). Five of
t chain % PC Histology
bda < 10 Endomyocardial biopsy
pa < 10 Skin biopsy
bda 5 Skin biopsy
bda 29 Skin biopsy
bda 8.5 Endomyocardial biopsy
pa 2 Endomyocardial biopsy
bda < 10 Skin biopsy
bda 10 Kidney biopsy
rs.
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3A. Mignot et al.
he six patients with renal involvement presented initially
ith nephrotic syndrome (Tables 1 and 3).
Cardiac manifestations were prominent at presentation:
ll patients had severe ﬂuid retention, with NYHA class 3
eart failure in seven cases. Electrocardiography showed
iffuse low voltage in ﬁve patients and ﬁrst degree atri-
ventricular conduction block associated with poor R wave
rogression in the precordial leads in four patients (Table 2).
n the three patients for whom BNP/NT-proBNP tests were
vailable, high serum levels were found at the time of diag-
osis (Table 2). Echocardiography ﬁndings were reviewed in
even cases. Restrictive cardiomyopathy was present in all
atients, associated invariably with left ventricular and sep-
al thickening (Fig. 1). Left atrial dilatation and pericardial
ffusion were observed in 6/6 and 6/8 patients, respec-
ively. Five patients had evidence of advanced amyloid heart
ailure, with a left ventricular ejection fraction (LVEF) less
han 50%.
Prior to heart transplantation, ﬁve patients received
hemotherapy with oral melphalan plus dexamethasone
MD) (Table 3); only patient six was offered intensive ther-
py with HDM/ASCT. Serial monthly measurements of sFLC
evels were performed in only two patients before and after
D therapy. Partial haematological response was obtained
fter three courses of MD in patient 2. In patient 8, complete
aematological response was observed after three courses
f MD, as illustrated by a rapid 80% reduction in the aberrant
FLC concentration, with a parallel decrease in NT-proBNP
evels (Fig. 3).
The mean time between the diagnosis of amyloid
ardiomyopathy and heart transplantation was 8.1± 7.9
onths (Table 4). The early postoperative period was
nremarkable in ﬁve patients. Patient 4 died from digestive
leeding 17 days after surgery, while patient 2 recovered
rom alveolar haemorrhage eight days post-transplantation.
n patient 6, endomyocardial biopsy demonstrated recur-
ence of AL amyloidosis on the allograft four months after
ransplantation. Renal function progressed to end-stage
enal failure in two patients: combined heart and kidney
ransplantation was performed in patient 7, while patient
received a kidney transplant 57 months after cardiac
ransplantation.
Following cardiac transplantation, four patients were
iven chemotherapy, after a mean period of 7.2± 3.6
onths. Patient 5, who was untreated previously, received
ix courses of MD. Patients 1 and 2, who had been given
D before heart transplantation, received HDM/ASCT; MD
herapy was reintroduced in both of these patients because
f a lack of response to HDM/ASCT. Patient 6 was offered
BMT six months after surgery because of haematologi-
al relapse following HDM/ASCT in the pretransplantation
eriod. Of these four patients, haematological response was
ot determined in one case (patient 1). Sustained complete
aematological response was obtained with MD chemother-
py in patients 2 and 5. Patient 6, in whom a haematological
esponse was not achieved following ABMT, died 50months
fter heart transplantation from systemic amyloid progres-
ion and recurrence in the transplanted heart. Among the
hree patients who received only MD therapy prior to heart
ransplantation, complete free light chain response was
aintained two years after MD in patient 8. In patients
and 7, the effect of chemotherapy was not assessed by
H
eart
transplantation
and
system
ic
am
yloidosis
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Table 3 Haematological therapy and response evaluation before and after heart transplantation.
Patient Extracardiac amyloid
involvement
Haematological
treatment
Response (sFLC) Time
(months)a
Transplantation Haematological
recurrence
Haematological
treatment
post-transplantation
Response
(sFLC)
1 Kidney/liver MD (3 courses) ND 7 Heart then kidney Yes HDM/ACST
then MD (2
months post-
transplantation)
ND
2 Kidney/liver/nervous
systemb/pulmonary/
skin/esophagus
MD (4 courses) Partial 5 Heart Yes HDM/ACST
then MD (10
months post-
transplantation)
Complete
3 Nervous systemb/skin MD (4 courses) ND 6 Heart No No Partial
4 Nervous
systemb/kidney/
liver/esophagus/skin
No NA 2 Heart NA No Progression
5 Kidney/nervous
systemb/skin
No NA 3 Heart NA MD (6 courses)
(11 months
post-
transplantation)
Complete
6 Nervous
systemb/liver/skin
HDM/ASCT ND 27 Heart Yes ABMT (6
months post-
transplantation)
Progression
7 Kidney/skin/esophagus MD (4 courses) ND 9 Heart and kidney No No Complete
8 Kidney/skin/nervous
systemb
MD (6 courses) Complete 6 Heart No No Complete
NA: not applicable.
a Time from amyloid diagnosis to heart transplantation.
b Peripheral and autonomic nervous system.
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Table 4 Heart transplantation data.
Patient Time
(months)a
Transplantation
(year)
Cold ischemia/CP bypass
time (minutes)
Donor (sex, age,
cause of death)
Rejection episodes:
ISHLT grade
Recurrence of
cardiac amyloidosis
Follow-up
(months)
1 7 Heart then
kidney (2002)
83/ND Male, 35 years,
CH
No No 58
2 5 Heart (2006) 221/180 Male, 23 years,
CH
No No 11
3 6 Heart (2005) 195/42 Female, 54
years, CH
No No 28
4 2 Heart (2006) 148/108 Female, 53
years, CH
ND ND 1.5
(death)a
5 3 Heart (2005) 202/123 Female, 49
years, CH
Yes: 3A (7 months
post-
transplantation)
No 23
6 27 Heart (2001) 180/58 Female, 32
years, CH
No Yes 50 (death)
7 9 Heart and
kidney (2005)
257/186 Female, 22
years, CH
Yes: 1B (8 months
post-
transplantation)
No 27
8 6 Heart (2005) 190/68 Male, 46 years,
CH
No No 25
CH: cerebral haemorrhage; CP: cardiopulmonary.
a Time from amyloid diagnosis to heart transplantation.
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Figure 1. Pretransplant echocardiographic data (patient 8). A. Parasternal long-axis view. Increased echogenicity of the myocardium and
valves, with pericardial effusion. Low mitral and aortic outﬂow. B. Apical 4-chamber view. Normal biventricular dimensions and biatrial
enlargement. Concentric left ventricular and atrial septum thickening. C. Tissue Doppler imaging recorded from the lateral mitral annulus.
Reduced myocardial velocity throughout systole and both phases of diastole, compatible with restrictive cardiomyopathy. D. Parasternal
erica
ss the
red
ishort-axis view. Concentric left ventricular thickening and small p
recorded from the mitral annulus: low ﬂow propagation velocity acro
Doppler ﬂow. Restrictive pattern with a short deceleration time and
serum free light chain measurements. However, in patient
7, serum kappa to lambda ratio was within the normal range
(0.64) at 27 months post-cardiac transplantation, indicat-
ing complete hematological remission. In patient 3, despite
abnormal serum levels of free lambda light chains (423mg/l,
with kappa to lambda ratio of 0.02), the patient remained
t
a
d
p
Figure 2. Endomyocardial biopsy before and after heart transplantat
Light microscopy, periodic acid-Schiff (PAS) staining, original magniﬁca
myocardial artery. B. Graft endomyocardial biopsy, 2 years post-transpla
amyloid deposits were detected in myocardial interstitium and arteriesrdial effusion. E. Apical 4-chamber view. Colour M-mode Doppler
cavity of the left ventricular. F. Apical 4-chamber view. Transmitral
uced A-wave velocity.
n good clinical condition after 28 months post transplanta-
ion. None of these three patients had evidence of recurrent
myloid deposits on the allograft.
After a median follow-up of 26 months, two patients had
ied; the clinical condition was good in the six remaining
atients, without evidence of systemic amyloid progression
ion (patient 8). A. Endomyocardial biopsy of the explanted heart.
tion x 400. Parietal amorphous oeosinophilic deposits in a small
nt. Light microscopy, PAS staining, original magniﬁcation x 400. No
(arrow). Mild inﬁltration by mononuclear cells.
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reatinine; Dex: dexamethasone.
r recurrence in the transplanted heart, as demonstrated by
outine follow-up endomyocardial biopsies (Fig. 2, Table 4)
Fig. 3).
iscussion
egardless of the nature of the amyloid precursor, cardiac
myloidosis is characterized by extracellular amyloid
nﬁltration throughout the heart, with deposits involving
entricles, atria, valves, and intracardiac vessels. The
nﬁltrative process results in biventricular wall thickening
ith non-dilated ventricles [2].
Typically, patients with heart failure resulting from
L amyloidosis present with rapidly progressive dysp-
oea, almost always associated with evidence of elevated
ight-sided ﬁlling pressure on echocardiography. Fluid reten-
ion, which manifests initially as peripheral oedema, may
e severe, particularly in patients with associated renal
nvolvement. In the present study, seven of the eight
atients had NYHA class 3 heart failure at the time of diag-
osis of AL amyloidosis. Additionally, six patients showed
ypical electrocardiographic changes including diffuse low
oltage, and or poor R-wave progression in the precordials
eads mimicking myocardial infarction.
NT-proBNP is a sensitive marker of myocardial dysfunc-
ion that has been shown recently to be a prognostic factor
n AL amyloidosis. Palladini et al. showed that a simultane-
us reduction in amyloidogenic free LC and NT-proBNP levels
ith chemotherapy was associated with rapid improvement
n cardiac function and prolonged survival. Interestingly,
hanges in NT-proBNP concentrations and cardiac function
ere not accompanied by signiﬁcant changes in the amount
f cardiac deposits, as evaluated by echocardiography. The
uthors suggested that myocardial dysfunction in AL amy-
oidosis could be related not only to the accumulation of
myloid deposits but also to direct cardiac toxicity exerted
w
d
o
a
1eart transplantation (patient 8). FLC: free light chain; SCr: serum
y critical concentrations of the amyloidogenic precursor
16]. Unfortunately, BNP or NT-proBNP levels were measured
n only three patients in the present study. In patient 8, a
imultaneous reduction in lambda light chain and NT-proBNP
evels with MD chemotherapy was associated with prolonged
urvival after heart transplantation. Altogether, these data
uggest that serial measurements of NT-proBNP levels should
e systematically performed in patients with AL amyloido-
is to detect early cardiac involvement or recurrence on the
llograft, and to evaluate the effect of treatment.
Doppler echocardiography is a key step in the diagnosis
f cardiac amyloidosis. The echocardiographic appearance
f advanced cardiac AL amyloidosis is characteristic, with
on-dilated ventricles, concentric left and right ventricular
hickening, prominent valves, and inﬁltration of the atrial
eptum. The myocardial texture is abnormal, with increased
chogenicity of the myocardium and the valves, referred
o as a ‘‘granular sparkling’’ pattern. Right ventricular
ree wall thickening, in the absence of pulmonary or sys-
emic hypertension, strongly suggests myocardial infarction,
hich should be conﬁrmed and identiﬁed by endomyocar-
ial biopsy. In advanced disease, Doppler echocardiography
ypically shows a restrictive transmitral ﬂow pattern, char-
cterized by a short E wave deceleration time and a low
elocity A wave. The decreased transmitral A wave in AL
myloidosis is not only related to endstage restrictive car-
iomyopathy, but also to atrial amyloid inﬁltration. The LVEF
s normal until late in the disease; when altered, it corre-
ates with a signiﬁcant reduction in short-term survival [2].
n the early stages of amyloid cardiomyopathy, the diagnosis
ay be challenging, as Doppler features depend on the stage
f the disease, with diastolic dysfunction that progresses
ith myocardial inﬁltration [2]. As mild degrees of diastolic
ysfunction are common among patients aged 50 years and
lder, this should not be used in isolation to diagnose cardiac
myloidosis. According to the consensus opinion from the
0th International Symposium on Amyloid and Amyloidosis,
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the echocardiographic criterion for the diagnosis of cardiac
amyloidosis is a mean left ventricular wall thickness (sep-
tum and posterior wall) greater than 12mm, in the absence
of hypertension or other causes of left ventricular hypertro-
phy [15]. In the present study, this criterion was present in
all seven patients, in whom echocardiographic ﬁndings were
available for review, together with features of diffuse hyper-
trophic cardiomyopathy and diastolic dysfunction (Table 2).
Despite limited experience, there is growing evidence
that cardiac transplantation may be life-saving in selected
patients with end-stage amyloid heart disease. However,
in systemic AL amyloidosis, both the criteria for eligibil-
ity for the procedure and the role of adjuvant therapies,
aimed at controlling the underlying plasma cell disorder
to prevent recurrence of amyloid deposits on the allograft
and systemic progression of the disease, remain contro-
versial. Since the ﬁrst description of successful Cardiac
transplantation in AL amyloidosis [4], only small multicen-
tric series or case reports have been published [5—13].
Recently, in a retrospective analysis of the United Network
for Organ Sharing (UNOS) database, Kpodonu et al. found
that the actuarial one and ﬁve-year survival rates of all
reported patients grafted for amyloid cardiomyopathy were
signiﬁcantly lower, compared to those with other cardiac
conditions (74.6% and 54% versus 81.6% and 63.8%, respec-
tively) [8]. Heart recipients with AL amyloidosis are at higher
risk compared to those transplanted for other causes of
amyloid cardiopathy, such as transthyretin or apolipopro-
tein AL amyloidosis. In seven patients with non-AL amyloid
cardiomyopathy, Dubrey et al. reported survival rates of 86,
86, and 64% at one, two, and ﬁve years, respectively. By
contrast, survival was 71, 71, and 36% at one, two, and
ﬁve years, respectively, in seven AL amyloid patients who
received post-transplant chemotherapy. In ten patients with
AL amyloidosis who underwent transplantation but did not
have additional chemotherapy, survival was only 50, 50, and
20%, respectively, with amyloid recurrence in the graft after
a median of 11 months. If both perioperative mortality and
incidence of allograft acute rejection were not signiﬁcantly
different compared to patients with non-AL amyloidosis,
progressive extracardiac accumulation of deposits after car-
diac transplantation contributed to mortality in 70% of AL
amyloid patients [9]. Thus, severity of extracardiac amyloid
organ involvement and its progression related to persistent
production of amyloid-forming monoclonal light chains are
major risk factors for mortality after heart transplantation in
AL amyloidosis patients. The achievement of haematological
remission appears to be a crucial point in the management
of these patients.
Serial measurements of sFLC levels, which are abnormal
in up to 98% of patients with AL amyloidosis, are manda-
tory for the evaluation of the haematological response after
chemotherapy. Sustained suppression of clonal disease, as
demonstrated by normalization or greater than 80% reduc-
tion in sFLC levels, is associated with prolonged survival
[16—18]. In the present study, haematological response was
evaluated monthly using the free light chain assay in only
four of the eight patients. In patient 8, achievement of
a complete clonal response, as demonstrated by a more
than 80% reduction in sFLC levels, was a strong argument
for the indication of cardiac transplantation, despite severe
systemic disease.
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In recent years, the overall prognosis of AL amyloidosis
as been transformed with the use of new therapies such as
DM followed by ASCT. Although this approach is effective
n controlling the source of amyloidogenic LC and inducing
mprovement in organ function and survival, the indica-
ions for HDM/ASCT are limited by high treatment-related
ortality in patients with multiple organ involvement [14].
ubstantial survival beneﬁt from sequential heart transplan-
ation and HDM/ASCT in AL amyloidosis was demonstrated
ecently by Gillmore et al., in ﬁve patients selected care-
ully for the absence of clinically signiﬁcant extracardiac
myloid. HDM/ASCT was performed with a median time of 13
onths from heart transplantation, as ﬁrst-line chemother-
py in four cases. This approach resulted in prolonged
urvival times of 91.1 and 76.4 months from heart trans-
lantation and HDM/ASCT, respectively. Three patients with
ustained suppression of clonal disease (as demonstrated
y normalization or greater than 80% reduction in sFLC
evels), had a normal performance status and no evidence of
ardiac or extracardiac amyloid accumulation after a mean
ollow-up period of 99 months from diagnosis. By contrast,
eath related to systemic and cardiac amyloid accumulation
ccurred in the two patients, in whom plasma cell dyscrasia
ailed to respond or relapsed after HDM/ASCT [10]. Recently,
ack et al. reported encouraging results in a series of seven
atients transplanted for AL amyloid cardiac disease. With
he exception of one patient who died from infection 201
ays after the procedure, all patients survived the proce-
ure and were free of cardiac symptoms. Chemotherapy was
erformed after cardiac transplantation in ﬁve patients,
ollowed by HDM/ASCT in one case, which resulted in haema-
ological remission in four patients (with normalization
f sFLC levels in three patients); no patient had evi-
ence of amyloid recurrence on the allograft. However, the
hemotherapy protocols used in this study were not detailed
11].
Owing to the systemic nature of the disease, only a
inority of patients with AL amyloidosis are eligible for
equential heart transplantation and high-dose chemother-
py [19]. In the present series, ﬁve patients received MD
efore heart transplantation because of the presence of
igniﬁcant symptomatic extracardiac manifestations, which
ere associated with a prohibitive risk of toxicity from
he tandem approach. The MD combination is an effective
herapy in AL amyloidosis. In a study of 46 patients who
ere ineligible for HDM/ASCT, 67% had a partial haema-
ological response and 33% a complete response with this
egimen (melphalan 0.22mg/kg and dexamethasone 40mg
iven orally on days one to four every 28 days). Reduction
n the monoclonal component was associated with improved
unction of the involved organ in 48% of patients, resulting in
signiﬁcant survival beneﬁt. The short time to haematolog-
cal response (median 4.5 months) probably accounted for
hese favourable results in patients with advanced disease
20]. Recently, in a randomized controlled trial involving
00 patients with systemic AL amyloidosis, MD resulted in
mproved overall survival compared with HDM/ASCT [21].
he present study also suggests that HDM/ASCT, which was
erformed as ﬁrst-line therapy in one patient, and as rescue
herapy in two patients, does not show improved efﬁcacy
ver MD therapy in AL amyloidosis patients requiring cardiac
ransplantation.
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In conclusion, heart transplantation may be associated
ith prolonged survival in AL amyloidosis heart disease,
hich remains largely under-diagnosed despite established
riteria. Prognosis appears to be related closely to the
chievement of clonal response with haematological ther-
py, either before or after surgery. The effect of treatment
n the production of amyloidogenic monoclonal LC should be
onitored carefully using sensitive techniques. For patients
neligible for HDM/ASCT because of signiﬁcant extracardiac
rgan involvement, conventional chemotherapy with MD
ppears to be a promising alternative. Close collaboration
etween physicians involved in the care of this rare disease
hould improve the overall prognosis of cardiac transplanta-
ion in patients with AL amyloidosis.
unding
his work was supported by a grant from AREN Poitou-
harentes.
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